Ivabradine for treating chronic heart failure
KEYWORDS: ivabradine, heart, failure, heart failure, population, committee, manufacturer, authorisation, marketing, marketing authorisation, patients, rate, standard, trial, mortality

(phosphenes), bradycardia, atrioventricular first degree, ventricular extrasystoles, blurred vision, headache, dizziness and uncontrolled blood pressure. For full details of adverse reactions and contraindications, see the summary of product characteristics. 2.3 Ivabradine is available in 5 mg and 7.5 mg tablets at a net price of £40.17 per 56-tablet pack (excluding VAT; BNF edition 63). The manufacturer's submission quoted an average monthly cost of £42.10 (excluding VAT) based on the proportion of patients using 2.5 mg (7%) and either 5 mg or 7.5 mg (93%) in the SHIFT study (see section 3.1). Costs may vary in different settings because of negotiated procurement discounts. 3 The manufacturer's submission The appraisal committee considered evidence submitted by the manufacturer of ivabradine and a review of this submission by the evidence review group (ERG). 3.1 The manufacturer conducted a systematic literature search and identified only 1 randomised controlled trial that assessed the effect of ivabradine in people with heart failure, known as SHIFT (systolic heart failure treatment with the If inhibitor ivabradine trial). SHIFT was an international, multicentre, randomised, double- blind, placebo-controlled trial comparing ivabradine with placebo for the treatment of moderate to severe heart failure and left ventricular systolic dysfunction. The trial was carried
